Zilovertamab vedotin

DB18457InvestigationalProtein Based Therapies

Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.

Mechanism: Pharmacologically active on Inactive tyrosine-protein kinase transmembrane receptor ROR1
Curator reviewed
Code names: MK-2140 · VLS-101

Resolves to

Compound

UNIIIZY9ZSI6FICAS2376463-48-6

Targets

Q01973ROR1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zilovertamab vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account